Page 40 - Read Online

Lee et al. Cancer Drug Resist 2020;3:980-91 I http://dx.doi.org/10.20517/cdr.2020.73 Page 991

mechanisms. Mol Cancer Ther 2015;14:2004-13.
7. Lee JM, Nair J, Zimmer A, et al. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade
serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lancet Oncol 2018;19:207-15.
8. Lowery CD, Dowless M, Renschler M, et al. Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or
chemopotentiator across a range of preclinical pediatric tumor models. Clin Cancer Res 2019;25:2278-89.
9. Lowery CD, VanWye AB, Dowless M, et al. The checkpoint kinase 1 inhibitor prexasertib induces regression of preclinical models of
human neuroblastoma. Clin Cancer Res 2017;23:4354-63.
10. Bryant C, Rawlinson R, Massey AJ. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
BMC Cancer 2014;14:570.
11. Choi C, Cho WK, Park S, et al. Checkpoint kinase 1 (CHK1) inhibition enhances the sensitivity of triple-negative breast cancer cells to
proton irradiation via Rad51 downregulation. Int J Mol Sci 2020;21:2691.
12. Ma CX, Cai S, Li S, et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse
tumor models. J Clin Invest 2012;122:1541-52.
13. Mani C, Jonnalagadda S, Lingareddy J, et al. Prexasertib treatment induces homologous recombination deficiency and synergizes with
olaparib in triple-negative breast cancer cells. Breast Cancer Res 2019;21:104.
14. Gatti-Mays ME, Karzai FH, Soltani SN, et al. A phase II single arm pilot study of the CHK1 inhibitor prexasertib (LY2606368) in BRCA
wild-type, advanced triple-negative breast cancer. Oncologist 2020; doi: 10.1634/theoncologist.2020-0491.
15. Booth L, Cruickshanks N, Ridder T, et al. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary
carcinoma cells. Cancer Biol Ther 2013;14:458-65.
16. Lee HJ, Cao Y, Pham V, et al. Ras-MEK signaling mediates a critical Chk1-dependent DNA damage response in cancer cells. Mol Cancer
Ther 2017;16:694-704.
17. Gonzalez-Conchas GA, Rodriguez-Romo L, Hernandez-Barajas D, et al. Epidermal growth factor receptor overexpression and outcomes
in early breast cancer: a systematic review and a meta-analysis. Cancer Treat Rev 2018;62:1-8.
18. Liu D, He J, Yuan Z, et al. EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a
retrospective analysis based on a tissue microarray. Med Oncol 2012;29:401-5.
19. Rimawi MF, Shetty PB, Weiss HL, et al. Epidermal growth factor receptor expression in breast cancer association with biologic
phenotype and clinical outcomes. Cancer 2010;116:1234-42.
20. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.
Pharmacol Rev 2006;58:621-81.
21. Sonavane M, Sykora P, Andrews JF, Sobol RW, Gassman NR. Camptothecin efficacy to poison Top1 is altered by bisphenol A in mouse
embryonic fibroblasts. Chem Res Toxicol 2018;31:510-9.
22. Yip C, Foidart P, Somja J, et al. MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to
chemotherapy and erlotinib. Br J Cancer 2017;116:742-51.
23. Schottle J, Chatterjee S, Volz C, et al. Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung
cancer. Oncotarget 2015;6:38458-68.
24. She QB, Solit DB, Ye Q, et al. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-
deficient tumor cells. Cancer Cell 2005;8:287-97.
25. Nair J, Huang TT, Murai J, et al. Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA
wild-type ovarian cancer. Oncogene 2020;39:5520-35.
26. Zeng L, Beggs RR, Cooper TS, Weaver AN, Yang ES. Combining Chk1/2 inhibition with cetuximab and radiation enhances in vitro and
in vivo cytotoxicity in head and neck squamous cell carcinoma. Mol Cancer Ther 2017;16:591-600.
27. Park HS, Jang MH, Kim EJ, et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Modern Pathol
2014;27:1212-22.
28. Matsuo T, Nishizuka SS, Ishida K, et al. Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft
models. BMC Res Notes 2011;4:140.
29. Kimple RJ, Vaseva AV, Cox AD, et al. Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is
mediated by inhibition of Akt independent of ras mutational status. Clin Cancer Res 2010;16:912-23.
30. Andersson MK, Aman P. Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and
vandetanib. Cancer Cell Int 2008;8:1.
31. Pahl JH, Ruslan SE, Buddingh EP, et al. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward
osteosarcoma. Clin Cancer Res 2012;18:432-41.